Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations are commonly observed in hormone receptor-positive breast cancer after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1 mutations at both the initial diagnosis of MBC and at each subsequent progression using liquid biopsy assays.